Continuous Vancomycin Infusion versus Intermittent Infusion in Critically Ill Patients

References

• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(Supplement_1):S35–S39. doi:10.1086/491712
   Web of Science ®Google Scholar
• DiMondi VP, Rafferty K. Review of continuous-infusion vancomycin. Ann Pharmacother. 2013;47(2):219–227. doi:10.1345/aph.1R420
   Web of Science ®Google Scholar
• Zamoner W, Prado IRS, Balbi AL, Ponce D. Vancomycin dosing, monitoring and toxicity: critical review of the clinical practice. Clin Exp Pharmacol Physiol. 2019;46:292–301. doi:10.1111/1440-1681.13066
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13):925–942. doi:10.2165/00003088-200443130-00005
   PubMed Web of Science ®Google Scholar
• Song KH, Kim HB, Kim HS, et al. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2015;46(6):689–695. doi:10.1016/j.ijantimicag.2015.09.010
   Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49(3):325–327. doi:10.1086/600877
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835–864. doi:10.1093/ajhp/zxaa036
   PubMed Web of Science ®Google Scholar
• Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001;45(9):2460–2467. doi:10.1128/aac.45.9.2460-2467.2001
   PubMed Web of Science ®Google Scholar
• Schmelzer TM, Christmas AB, Norton HJ, Heniford BT, Sing RF. Vancomycin intermittent dosing versus continuous infusion for treatment of ventilator-associated pneumonia in trauma patients. Am Surg. 2013;79(11):1185–1190. doi:10.1177/000313481307901123
   PubMed Web of Science ®Google Scholar
• Hong LT, Goolsby TA, Sherman DS, et al. Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients. J Crit Care. 2015;30(5):1153e1–6. doi:10.1016/j.jcrc.2015.06.012
   Web of Science ®Google Scholar
• Bissell BD, Riggi G, Morrison C. Evaluation of continuous infusion vancomycin administration in a critically ill trauma population. J Intensive Care Med. 2020;35(6):570–575. doi:10.1177/0885066618768749
   Web of Science ®Google Scholar
• Flannery AH, Bissell BD, Bastin MT, Morris PE, Neyra JA. Continuous versus intermittent infusion of vancomycin and the risk of acute kidney injury in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2020;48(6):912–918. doi:10.1097/CCM.0000000000004326
   PubMed Web of Science ®Google Scholar
• Hao JJ, Chen H, Zhou JX. Continuous versus intermittent infusion of vancomycin in adult patients: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016;47(1):28–35. doi:10.1016/j.ijantimicag.2015.10.019
   PubMed Web of Science ®Google Scholar
• Raverdy V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother. 2013;68(5):1179–1182. doi:10.1093/jac/dks510
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi:10.1159/000180580
   PubMed Web of Science ®Google Scholar
• Waineo MF, Kuhn TC, Brown DL. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion. J Clin Pharm Ther. 2015;40(3):259–265. doi:10.1111/jcpt.12270
   Web of Science ®Google Scholar
• Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. doi:10.1186/cc5713
   PubMed Web of Science ®Google Scholar
• Tafelski S, Nachtigall I, Troeger U, et al. Observational clinical study on the effects of different dosing regimens on vancomycin target levels in critically ill patients: continuous versus intermittent application. J Infect Public Health. 2015;8(4):355–363. doi:10.1016/j.jiph.2015.01.011
   PubMed Web of Science ®Google Scholar
• Saugel B, Nowack MC, Hapfelmeier A, et al. Continuous intravenous administration of vancomycin in medical intensive care unit patients. J Crit Care. 2013;28(1):9–13. doi:10.1016/j.jcrc.2012.02.003
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? Clin Pharmacokinet. 2008;47(3):147–152. doi:10.2165/00003088-200847030-00001
   Web of Science ®Google Scholar
• Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(1):17–24. doi:10.1093/jac/dkr442
   PubMed Web of Science ®Google Scholar